Annual Working Capital
$115.55 M
+$102.62 M+793.44%
March 31, 2024
Summary
- As of February 24, 2025, VTGN annual working capital is $115.55 million, with the most recent change of +$102.62 million (+793.44%) on March 31, 2024.
- During the last 3 years, VTGN annual working capital has risen by +$15.62 million (+15.63%).
- VTGN annual working capital is now at all-time high.
Performance
VTGN Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Working Capital
$80.32 M
-$12.11 M-13.10%
December 31, 2024
Summary
- As of February 24, 2025, VTGN quarterly working capital is $80.32 million, with the most recent change of -$12.11 million (-13.10%) on December 31, 2024.
- Over the past year, VTGN quarterly working capital has dropped by -$24.28 million (-23.21%).
- VTGN quarterly working capital is now -35.20% below its all-time high of $123.95 million, reached on December 31, 2023.
Performance
VTGN Quarterly Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Working Capital Formula
Working Capital = Current Assets − Current Liabilities
VTGN Working Capital Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +793.4% | -23.2% |
| 3 y3 years | +15.6% | -23.2% |
| 5 y5 years | +967.1% | -23.2% |
VTGN Working Capital Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +793.4% | -35.2% | +966.7% |
| 5 y | 5-year | at high | +9801.0% | -35.2% | +5266.9% |
| alltime | all time | at high | +768.6% | -35.2% | +564.8% |
VistaGen Therapeutics Working Capital History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | - | $80.32 M(-13.1%) |
| Sep 2024 | - | $92.42 M(-11.6%) |
| Jun 2024 | - | $104.60 M(-9.5%) |
| Mar 2024 | $115.55 M(+793.4%) | $115.55 M(-6.8%) |
| Dec 2023 | - | $123.95 M(+242.7%) |
| Sep 2023 | - | $36.17 M(+380.3%) |
| Jun 2023 | - | $7.53 M(-41.8%) |
| Mar 2023 | $12.93 M(-80.2%) | $12.93 M(-40.6%) |
| Dec 2022 | - | $21.77 M(-29.5%) |
| Sep 2022 | - | $30.87 M(-33.0%) |
| Jun 2022 | - | $46.07 M(-29.4%) |
| Mar 2022 | $65.23 M(-34.7%) | $65.23 M(-18.8%) |
| Dec 2021 | - | $80.35 M(-9.2%) |
| Sep 2021 | - | $88.53 M(-5.4%) |
| Jun 2021 | - | $93.56 M(-6.4%) |
| Mar 2021 | $99.93 M(-8489.6%) | $99.93 M(-2.0%) |
| Dec 2020 | - | $102.01 M(+705.2%) |
| Sep 2020 | - | $12.67 M(-2663.8%) |
| Jun 2020 | - | -$494.20 K(-58.5%) |
| Mar 2020 | -$1.19 M(-111.0%) | -$1.19 M(-23.4%) |
| Dec 2019 | - | -$1.55 M(-377.8%) |
| Sep 2019 | - | $559.60 K(-89.8%) |
| Jun 2019 | - | $5.47 M(-49.5%) |
| Mar 2019 | $10.83 M(+13.2%) | $10.83 M(+109.3%) |
| Dec 2018 | - | $5.17 M(-27.9%) |
| Sep 2018 | - | $7.17 M(+20.0%) |
| Jun 2018 | - | $5.98 M(-37.5%) |
| Mar 2018 | $9.56 M(+375.8%) | $9.56 M(-24.4%) |
| Dec 2017 | - | $12.65 M(+2752.0%) |
| Sep 2017 | - | $443.40 K(-60.5%) |
| Jun 2017 | - | $1.12 M(-44.2%) |
| Mar 2017 | $2.01 M | $2.01 M(-48.4%) |
| Dec 2016 | - | $3.90 M(-23.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2016 | - | $5.11 M(-27.4%) |
| Jun 2016 | - | $7.03 M(-848.7%) |
| Mar 2016 | -$939.40 K(-94.6%) | -$939.40 K(+337.1%) |
| Dec 2015 | - | -$214.90 K(-61.0%) |
| Sep 2015 | - | -$551.30 K(-67.3%) |
| Jun 2015 | - | -$1.68 M(-90.3%) |
| Mar 2015 | -$17.28 M(+234.6%) | -$17.28 M(+61.7%) |
| Dec 2014 | - | -$10.69 M(+59.4%) |
| Sep 2014 | - | -$6.70 M(+18.8%) |
| Jun 2014 | - | -$5.64 M(+9.2%) |
| Mar 2014 | -$5.17 M(+196.4%) | -$5.17 M(+42.6%) |
| Dec 2013 | - | -$3.62 M(+16.8%) |
| Sep 2013 | - | -$3.10 M(+14.4%) |
| Jun 2013 | - | -$2.71 M(+55.4%) |
| Mar 2013 | -$1.74 M(-40.8%) | -$1.74 M(-29.4%) |
| Dec 2012 | - | -$2.47 M(-5.6%) |
| Sep 2012 | - | -$2.62 M(-31.9%) |
| Jun 2012 | - | -$3.84 M(+30.5%) |
| Mar 2012 | -$2.94 M(>+9900.0%) | -$2.94 M(+52.1%) |
| Dec 2011 | - | -$1.94 M(-66.4%) |
| Sep 2011 | - | -$5.76 M(+45.3%) |
| Jun 2011 | - | -$3.97 M(>+9900.0%) |
| Mar 2011 | - | -$600.00(-57.1%) |
| Dec 2010 | -$1400.00(+55.6%) | -$1400.00(+27.3%) |
| Sep 2010 | - | -$1100.00(-375.0%) |
| Jun 2010 | - | $400.00(-157.1%) |
| Mar 2010 | - | -$700.00(-22.2%) |
| Dec 2009 | -$900.00(-104.7%) | -$900.00(-400.0%) |
| Sep 2009 | - | $300.00(>+9900.0%) |
| Jun 2009 | - | $0.00(-100.0%) |
| Dec 2008 | $19.10 K | $19.10 K(-645.7%) |
| Jun 2008 | - | -$3500.00(+45.8%) |
| Mar 2008 | - | -$2400.00 |
FAQ
- What is VistaGen Therapeutics annual working capital?
- What is the all time high annual working capital for VistaGen Therapeutics?
- What is VistaGen Therapeutics annual working capital year-on-year change?
- What is VistaGen Therapeutics quarterly working capital?
- What is the all time high quarterly working capital for VistaGen Therapeutics?
- What is VistaGen Therapeutics quarterly working capital year-on-year change?
What is VistaGen Therapeutics annual working capital?
The current annual working capital of VTGN is $115.55 M
What is the all time high annual working capital for VistaGen Therapeutics?
VistaGen Therapeutics all-time high annual working capital is $115.55 M
What is VistaGen Therapeutics annual working capital year-on-year change?
Over the past year, VTGN annual working capital has changed by +$102.62 M (+793.44%)
What is VistaGen Therapeutics quarterly working capital?
The current quarterly working capital of VTGN is $80.32 M
What is the all time high quarterly working capital for VistaGen Therapeutics?
VistaGen Therapeutics all-time high quarterly working capital is $123.95 M
What is VistaGen Therapeutics quarterly working capital year-on-year change?
Over the past year, VTGN quarterly working capital has changed by -$24.28 M (-23.21%)